Celliance has acquired gene expression technology for an undisclosed sum from a UK product development company...
Celliance has acquired gene expression technology for an undisclosed sum from a UK product development company. The ubiquitous chromatin opening element (UCOE) technology was deemed as non-core to Innovata after a strategic review by its new management team earlier this year.
UCOEs are said to improve the yield, consistency and stability of protein production in cultured mammalian cells, which allows simpler and quicker generation of proteins at small-scale for R&D. There is also the capacity for larger-scale manufacture of protein therapeutics, using stable, highly productive cell-lines, which are easily isolated with the technology.
The technology is under license to several pharmaceutical companies in North America, Europe and Japan. The separation from UCOEs is a move by the UK based company to refocus attention to respiratory disease and inhaled therapies. The assets that will be transferred to Celliance have no book value.
For more information about Celliance Corporation, please visit the website at